ArticlePatient preference and adherence2025
Impact of Systemic Lupus Erythematosus on Health-Related Quality of Life in Colombian Patients: A Cross-Sectional Analytical Study.
Article in Patient preference and adherence, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To describe the impact of systematic lupus erythematosus (SLE) on health-related quality of life (HRQL) compared with healthy subjects. Methods: This was an analytical cross-sectional study of 50 patients with SLE and 50 healthy controls. Sociodemographic, clinical and treatment variables were included. The diagnosis of SLE was made according to the classification criteria of the American College of Rheumatology/European League Against Rheumatism, and the activity of the disease was evaluated with the SLEDAI-2K. The reliability, internal consistency and discriminant power of the SF-36 were evaluated. The information analysis included summary measures, Pearson's chi-square test, Mann‒Whitney's Results: Forty-eight percent of the patients were women with an average age of 43.4 ± 14.8 years, 74% presented with comorbidities, and 22% were hospitalized in the last six months due to their illness. Seventy percent of the patients received corticosteroids, 62% with immunomodulators and 10% with biological treatments. SLE significantly impacts the domains of HRQL related to physical function, body pain, social function, emotional role, and general health. The factors that explain this impact on HRQL are having comorbidity with fibromyalgia, receiving treatment with DNA synthesis inhibitors and receiving corticosteroid treatments. The SF-36 presents good psychometric performance in the study group. Conclusion: SLE results in a deterioration in the HRQL of patients, as reflected in the domains of body pain and the perception of general health. This effect is more pronounced in patients who also have fibromyalgia. The mental health domain was more affected in those who received corticosteroid treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.